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painful relief is up to 75% in combined treatment group,
28.6% in control group.
Conclusion: Regional high-frequency hyperthermia com-
bined with TACE get better effect than TACE merely, without
sever side effect, be worth applying in clinical.
PP-043 Clinical analysis of 145 cases with spontaneous
bacterial peritonitis
L. Xiao*, E.G. Nu, N.Y. Sha, H. Liu, Y.X. Zhang. Department
of Infectious Diseases, Afﬁliated Hospital, Xinjiang Medical
University, Urumqi 830054, China
Objective: To evaluate the characteristics of clinical
manifestation and laboratory tests of spontaneous bacterial
peritonitis (SBP). To improve the level of diagnose
and treatment in patients with spontaneous bacterial
peritonitis.
Methods: A retrospective analysis of 145 patients with
SBP was performed, including the general data, cause of
disease, clinical manifestation, laboratory examination and
prognosis. All cases were performed with blood routine test,
blood clotting function and biochemical tests. 121 cases
were performed with ascites routine tests and ascites
cultures. All patients were given antibacterials of third
generation cephalosporin and/or quinolones on the basis of
routine supportive therapy.
Results: Among these study the patients with cirrhosis were
130 (89.66%), including 77 cases (53.10%) with hepatitis B,
27 cases (18.62%) with hepatitis C, 9 cases (6%) with primary
biliary cirrhosis, 12 cases (8%) with alcoholic cirrhosis,
5 cases (3%) with cryptogenic cirrhosis, 15 cases (10%) with
severe hepatitis. In clinical manifestation, 35 cases (24.14%)
with fever, 61 cases (42.06%) with abdominal pain, 76 cases
(52.41%) with abdominal distension, 29 cases (20%) with
diarrhea, 48 cases (33.10%) with hypourocrinia, 25 cases
(17.24%) with abdominal rigidity, 65 cases (44.82%) with
abdominal tenderness, 21 cases (14.48%) with abdominal
rebound pain. In 37 cases (22.52%), peripheral white blood
cell counts were >10× 109/L, 4 10×109/L in 86 cases
(59.31%), <4× 109/L in 22 cases (15.17%). 102 cases (70.35%)
whose eutrophil percentage was >70%. 91 cases (62.75%)
whose serum albumin level were <30 g/L. 94 cases (64.8%)
whose INR were >1.5. In 86 cases (71.2%) whose ascites
white cell counts were >250× 106/L, in 95 cases (78.5%)
whose polymorphonuclear cell percentage was >25%, in
97 cases (85.16%) whose ascites albumin level were <30 g/L
Ascites culture positive rate were 21.49% (26/121), among
them gram stain negative (G ) bacteria were 17 cases
(65.38%), gram stain positive (G+) were 9 cases (34.61%).
83 cases with other common complications, among them 61%
patients were died, 39% patients were survival. All patients
with hepatorenal syndrome were died. In quinolones
antibacterials group, 20 cases were survival (71%), in third
generation cephalosporin antibacterials group, 29 cases
were survival (78%), in combined antibacterials group, and
72 cases were survival (91%).
Conclusion: Cirrhosis was the most common cause of
SBP. The symptoms and signs of SBP were atypical.
Abdominal Pain, abdominal distention and abdominal
tenderness were common. Peripheral blood leucocyte
counts were less increased, but most cases whose eutrophil
percentage were >70%. 90% cases with hypoproteinemia
and coagulation disorders. Acites white cell counts and
polymorphonuclear cell percentage had high diagnostic
value for SBP patients. Ascites culture positive rate
were low. The main positive bacteria were gram stain
negative (G ) bacteria. Hepatorenal syndrome was the
most severe and fetal complication of SBP. Combined use
of antibacterials increased the therapeutic effects and
improves the prognosis of patients with SBP.
PP-044 Basella alba extract act as antitumour
and antioxidant potential against
N-nitrosodiethylamine induced hepatocellular
carcinoma in rats
G.D. Reddy1 *, R. Kartik2, Ch.V. Rao2, M.K. Unnikrishnan3,
P. Pushpangadan2. 1Dept of Pharmacology, CRIA, Bidhan
nagar, Kolkata-700 091, W.B., India, 2Department of
Ethnopharmacology, National Botanical Research Institute
(CSIR), Rana Pratap Marg, Lucknow-226001, 3Department
of Pharmacology, College of Pharmaceutical Sciences,
Madav nagar, Manipal-576104, Karnataka, India
The aqueous ethanolic plant leaves extract of Basella
alba (100, 200 and 400mg/kg bw) were administered to
animals signiﬁcantly inhibited hepatocarcinogenesis induced
by N-nitrosodiethylamine (NDEA) and CCl4 (promoter) in a
dose dependent manner. Their effect on tumour incidence,
levels of liver cancer markers and liver injury markers
evaluated the anticarcinogenic activity of the extract.
Animals treated with single injection of NDEA (200mg/kg
bw. ip) & CCL4 (3ml/kg bw/week. sc) for 6 weeks group
showed 100% tumour incidence. The level of g-gamma
glutamyl transpeptidase (GGT) in both serum and liver
was found to be elevated in tumour bearing animals,
while they were signiﬁcantly reduced upon treatment with
treated group. Serum levels of Aspartate aminotransaminase
(SGOT) and alanine aminotransferase (SGPT), and Alkaline
phosphatase (ALP), which are markers of liver injury,
were elevated in groups treated with NDEA & CCL4.
Administration of plant extract recuped back to near normal
in a dose dependent manner. Animals treated with NDEA &
CCL4 group signiﬁcantly elevated tissue levels of drug
metabolizing enzymes such as glutathione S-transferase
(GST) and Glutathione (GSH) and Glutathione peroxidase
(Gpx). Upon treatment with extract signiﬁcantly reduced
these levels in a dose dependent manner. The level of
lipid peroxidation (LPO) markedly increased in NDEA & CCL4
treated groups, which was brought back to near normal by
B. alba treatment. In contrast the activities/levels of the
Superoxide dismutase (SOD) and Catalase status in the liver
were decreased in NDEA& CCL4 administered animals, which
was recouped back to near normal upon treatment with
B. alba extract. Histopathological studies of liver tissues
showed a gradual development of normal architecture upon
treatment with the extract and levels of marker enzymes
indicated that the extract offered a good antioxidant and
greater protection against chemical carcinogenesis induced
hepatocarcinogenesis.
PP-045 A clinical investigation of plasma actin-free
Gc-globulin in chronic or acute-on-chronic liver
failure patients caused by hepatitis B virus
H. Liu*, T. Han. Tianjin Medical University Graduate
Schools, Tianjin Third Central Hospital, Tianjin 300170,
China
Aim: To investigate the relationship between plasma Actin-
Free Gc-globulin levels and chronic or acute-on-chronic liver
failure caused by Hepatitis B virus.
Methods: Plasma actin-free Gc globulin in 56 liver failure
patients, 23 cirrhosis (all were infected by HBV) and
25 healthy controls were measured by ELISA. Serum ALT,
AST, TBIL, CHE, ALB and Plasma INR, PLT levels were also
detected. Meanwhile, the Child-Pugh score was calculated
for each patient on admission.
Results: Plasma Af-Gc globulin levels in chronic liver
failure (CLF), acute-on-chronic liver failure (ACLF) and
cirrhosis (CR) were statistically signiﬁcantly lower than
that of healthy controls. The Af-Gc globulin level for
the liver failure was signiﬁcantly reduced compared with
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that of cirrhosis group (P 0.001); additionally, there was
statistically signiﬁcant difference between CLF and ACLF
patients (P< 0.001). Plasma Af-Gc globulin signiﬁcantly
positive correlated with ALB, ALT, AST, CHE (P was 0.001,
0.001, 0.001, <0.001 respectively), while weak positive
correlated with TBIL, PLT. Meanwhile, there was signiﬁcantly
negative correlation between plasma Af-Gc globulin and
Child Pugh score (P= 0.02), while weak negative correlated
with INR. The level of Af-Gc globulin in liver failure
patients who were infected by ascites or hydrothorax were
markedly lower than that of non-infected (P= 0.015), the
levels of Af-Gc in encephalopathy presence were lower
than encephalopathy absent (P= 0.083). No statistically
signiﬁcant difference was noted in non-survivors and
survivors of liver failure patients.
Conclusions: Plasma Af-Gc globulin levels in liver failure
patients were signiﬁcantly reduced compared with cirrhosis
and healthy controls, but it can not be used to evaluate the
prognosis of liver failure patients.
Abbreviations: Alanine aminotransferase (ALT), aspartate
aminotransferase (AST), choline esterase (CHE), Albumin
(ALB), total bilirubin (TBIL), palsma international
normalized ratio of prothrombin time (INR), platelet (PLT)
PP-046 The modiﬁed Sugiura procedure in treating
variceal hemorrhage: a retrospective analysis of
117 cases
K. Zhang*, Y. Mu, L. Jiang. Department of General Surgery,
the Beijing Ditan Hospital, Beijing 100011, China
Objective: To evaluate the clinic effects of the modiﬁed
Sugiura procedure in treating gastroesophageal varices
bleeding.
Methods: Between April 2001 and December 2006,
117 patients with varices bleeding were treated with
the modiﬁed Sugiura procedure. Its clinic data were
retrospective analyzed. At the same time the clinic
data of 94 cases about the Hassab procedure between
July 1996 and March 2001 were taken as control group.
Operative complications, residual varices, recurrence of
varices bleeding and encephalopathy were observed.
Results: Two groups were not dead cases, encephalopathy
cases and recurrence cases of varices bleeding in the
duration of hospital stay. Sugiura group had 4 cases of
digestive tract leakage and 2 cases of esophageal stricture
relating with stapler transaction. Sugiura group and Hassab
group had 4 and 3 portal vein thrombosis cases respectively
(P> 0.05). At the ﬁrst year of post-operation, residual varices
rate was 21.3% in Sugiura group and 50% in Hassab group
(P< 0.05), and recurrent rate of varices bleeding was 0 in
Sugiura group and 10.3% in Hassab group (P< 0.05).
Conclusion: The modiﬁed Sugiura procedure has a good
effect in treating varices bleeding. It is better than
the Hassab procedure in diminishing residual varices and
preventing recurrence of varices bleeding.
PP-047 Apoptosis, inﬂammation and ﬁbrosis in
acute alcoholic hepatitis with intrahepatic
cholestasis
V. Sondore1 *, J. Keiss1, N. Sevastjanova1, L. Viksna2,
B. Rozentale1. 1State agency “Infectology Center of
Latvia”, Riga, Latvia, 2Infectology Chair of Riga Stradins
University, Riga, Latvia
Introduction: According to recent concepts, pathologically
upregulated apoptosis in the liver both directly and
indirectly promotes inﬂammation and ﬁbrosis.
The aim of this study was to estimate apoptotic,
inﬂammatory and ﬁbrotic process in acute alcoholic
hepatitis with cholestasis.
Patients and Methods: 21 persons (alcohol surrogate users)
were admitted to Infectology Center of Latvia and diagnosed
with acute alcoholic hepatitis with intrahepatic cholestasis.
Diagnosis was conﬁrmed on the basis of clinical, biochemical
and morphological examination data. For comparison,
26 patients with acute alcoholic hepatitis without
cholestasis were included in this study. Serum level of
apoptosis marker cytokeratin 18 (CK-18) neoepitope (M30-
Apoptosense® ELISA kit, PEVIVA), ALT activity, C-reactive
protein and ﬁbrosis marker hyaluronic acid (ELISA, Corgenix
Inc., Colorado, USA) were detected.
Results: Obtained data show a high level of
CK-18 in patients with acute alcoholic hepatitis
with cholestasis (967.11± 111.20U/L) and without
cholestasis (1091.67± 153.30U/L; 40% <P< 50%). Serum
ALT activity in alcohol surrogate users was signiﬁcantly
higher (169.57± 47.54U/L) than in patients who used
qualitative ethanol (33.62± 3.27U/L; 99% <P< 99.9%).
Serum C-reactive protein level was signiﬁcantly higher
in patients without cholestasis (42.27± 6.79mg/L) than
in patients with cholestasis (27.13± 9.24mg/L; P> 99.9%).
Hyaluronic acid concentration was very high in sera of
patients with acute alcoholic hepatitis without cholestasis
(1006.46± 56.96 ng/ml) if compared with cholestatic acute
alcoholic hepatitis (271.67± 44.33 ng/ml; P> 99.9%).
Conclusion: Liver cell death in acute alcoholic hepatitis
is partially due to necrosis, but there is evidence that
apoptosis plays an important role in development of cell
injury. The extent of apoptosis process in clinical practice
usually is underestimated.
PP-048 Prediction value of MELD scoring system on
prognosis in patients with acute-on-chronic
hepatitis B liver failure after plasma exchange
and lamivudine treatment
J.W. Yu*, L.J. Sun, Y.H. Zhao, S.C. Li. Department of
Infectious Diseases, Second Afﬁliated Hospital, Harbin
Medical University, Harbin 150086, China
Background and Aim: We use model for end-stage liver
disease (MELD) scoring system to predict 3-month prognosis
of patients with acute-on-chronic liver failure (ACLF) after
plasma exchange (PE) and lamivudine treatment and study
the predictive factors on the prognosis of patients.
Methods: 280 patients treated with lamivudine were
randomly divided into PE and control groups. The
relationship of mortality and inﬂuential factors of patients
were studied by univariate and multivariate analysis.
Results: The mortality (49.4%) of patients in PE group with
MELD score from 30 to 40 was lower than that (86.1%) of
control group (c2 = 24.546, P < 0.01). TBIL rebound rate of
dead group was signiﬁcantly higher than that of survival
group (P < 0.01). Univariate analysis showed that mortality
was signiﬁcantly related to age (P = 0.003), treatment
method (P = 0.000), TBIL (P = 0.010), MELD score (P = 0.001),
INR (P = 0.014), pretreatment HBVDNA load (P = 0.000),
decline of HBVDNA load during therapy (P = 0.013),
encephalopathy (P = 0.019) and hepatorenal syndrome
(P = 0.026). In multivariate analysis, in patients with MELD
scores 30 40, treatment method (P = 0.003), pretreatment
HBVDNA load (P = 0.009), decline of HBVDNA load during
therapy (P = 0.016) and encephalopathy (P = 0.015) were
independent predictors of mortality; for MELD scores
above 40, only MELD score (P = 0.012) was independent
predictive.
Conclusions: PE signiﬁcantly decreases the mortality of
patients with MELD score 30 40. For ACLF patients with
MELD score 30 40, a low viral load pre-treatment and quick
decline of HBVDNA load are good predictors for the survival
of PE and lamivudine treatment.
